In 731 patients with untreated advanced HER2-negative gastric/GEJ adenocarcinoma, retlirafusp alfa plus CAPOX improved OS vs placebo plus CAPOX (median 15.8 vs 11.2 months, HR 0.66; CPS ≥5: 16.8 vs 10.4, HR 0.53). Grade ≥3 toxicity similar.
RCTn = 731
Peng et al. First-Line Retlirafusp Alfa Plus Chemotherapy for Human Epidermal Growth Factor Receptor 2-Negative Gastric or Gastroesophageal Junction Adenocarcinoma: A Randomized, Double-Blind, Phase III Study (RELIGHT)